CRL logo

Charles River Laboratories

CRL · What the business does, what can go wrong, and how options sellers approach it

What it does

Charles River Laboratories is a contract research organization (CRO) that supports the early stages of drug development. Pharmaceutical, biotech, and other life sciences customers use it to test whether a potential medicine is safe and effective before it reaches human trials.

The company works in three broad areas. One supplies purpose-bred research models for laboratory studies. Another provides discovery and safety assessment services, which cover early research and preclinical testing. The third is manufacturing support, which includes quality-control testing products and services for biologic and other drug production.

How it makes money

Customers pay fees for studies and services, and the company also sells research models and testing products. Many projects run over months, so revenue depends on how much work customers commission and how quickly projects move forward.

Backlog, meaning work booked but not yet completed, gives some visibility into future demand.

Why investors own it

Investors often use it for exposure to drug research spending without depending on any single drug succeeding. Its scale, long customer relationships, and range of services can make it a convenient partner for clients that prefer fewer vendors.

What can go wrong

Demand depends on customer funding. When biotech financing tightens or large drug companies cut research budgets, orders can slow quickly.

Other risks:

  • Animal research faces ethical scrutiny, and regulators and researchers are encouraging alternative methods, which could change demand over time.
  • Competition from other research service providers can pressure pricing.
  • Supply of research animals and facility capacity can be difficult to manage.
  • Acquisitions can disappoint or add complexity.

What to watch

  • Net bookings and book-to-bill ratio
  • Backlog trends
  • Biotech funding conditions
  • Customer cancellations and project delays
  • Operating margin
  • Regulatory developments on non-animal testing methods
  • Organic revenue growth

Options income angle

Options on CRL are available across several expirations but are usually less liquid than those on the largest stocks, with wider bid-ask spreads, especially for strikes far from the current price.

Implied volatility tends to rise ahead of earnings and around shifts in biotech funding, drug-industry spending, or regulation.

One caution for premium sellers: a large earnings-related move can turn a covered call or cash-secured put into a loss or forgone gains.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 27, 2025, filed February 18, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Charles River's 2025 revenue was nearly flat, but large write-downs in its manufacturing and cell businesses turned a small prior-year profit into a net loss. The filing also shows a company reshaping itself: a Board-led strategic review, cost cuts, planned sales of non-core assets, and the purchase of a Cambodian primate supplier.

How the business did

  • Revenue was $4.02 billion compared to $4.05 billion in fiscal year 2024, a decrease of 0.9%. Discovery and Safety Assessment (DSA) fell on lower study volume from cautious client spending. Research Models and Services (RMS) rose on large research models and higher pricing for small models.
  • Operating income was $25.2 million and 0.6%, compared with $227.3 million and 5.6%. The main cause was intangible asset impairment charges, which are non-cash write-downs when acquired assets are judged worth less than their recorded value. Net loss to common shareholders was $144.3 million, versus net income of $10.3 million.
  • Microbial Solutions grew robustly. Biologics Solutions was weak, with lost key CDMO (contract development and manufacturing) customers and a commercial cell therapy relationship that ended. DSA backlog decreased to $1.9 billion from $2.0 billion.
  • Cash flow from operations was $737.6 million compared with $734.6 million. The company repurchased 2.1 million shares for $350.0 million and made net repayments of $111.2 million on its Credit Facility.
  • The DOJ closed its primate-import investigations in August 2025. On November 14, 2025, the SEC said it did not intend to recommend an enforcement action.

Risks specific to this company

  • Non-human primate (NHP) supply comes from limited sources. Shipments from Cambodia were suspended in 2023, and the company received USFWS CITES clearance to import them in November 2025 and resumed. Tariffs are also in effect with countries that supply the company, including Vietnam, Mauritius, Cambodia and China.
  • Regulators are encouraging alternatives to animal testing. The FDA announced steps in April and October 2025, and the U.K. announced a roadmap in November 2025. The filing says eliminating animals in research may have material adverse effects, though it expects the shift to be gradual.
  • Biologics Solutions took a goodwill impairment charge of $165.0 million. The filing warns that lower cash flow expectations could bring a further material impairment. In January 2025, an FDA inspection of a company facility led to a CDMO client receiving a complete response letter on its drug application.
  • A putative securities class action and two derivative lawsuits allege that disclosures about primate importation were false or misleading.
  • The company had $2.1 billion of debt and finance leases as of December 27, 2025, which could limit financing options and flexibility.
  • RMS sells to academic clients that depend on government funding. In August 2025, the Supreme Court ruled in a way that allowed nearly $800 million in federal grants to be terminated.

What management is watching

  • Cost savings are expected to total approximately $300 million in cumulative, annualized cost savings by the end of 2026, of which more than $175 million benefitted fiscal 2025. Restructuring charges were $99.8 million.
  • The strategic review aims to strengthen the core portfolio through acquisitions, partnerships and internal investment. It also plans to divest non-core assets, which represent approximately 7% of 2025 revenue.
  • The KF (Cambodia) acquisition closed on January 14, 2026 at a purchase price of $510.0 million, of which $335.0 million was paid up-front. The PathoQuest purchase for €51.6 million is expected to close in the first quarter of 2026.
  • Capital return continues: a new $1.0 billion stock repurchase authorization was approved on October 29, 2025.
  • Management says demand from biopharmaceutical clients stabilized and began to show early signs of improvement. It points investors to net bookings and backlog as DSA demand signals.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 26, 2026, filed November 4, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Charles River's revenue for the quarter decreased 2.2% to $982.7 million, but operating income rose to $202.6 million from $133.8 million. Net income attributable to common shareholders rose to $333.1 million from $54.4 million, largely because of a $201 million tax benefit tied to a foreign tax law change. The business sold three units in May 2026, and those sales lowered revenue while helping margins.

How the business did

  • Revenue: Revenue for the three months decreased $22.1 million to $982.7 million. For the nine months it decreased 1.3% to $2,982.6 million. The company attributes the declines to the sale of its CDMO (contract development and manufacturing), Cell Solutions and certain European Discovery Services businesses.
  • Profit: Operating income was 20.6% of revenue, compared with 13.3% a year earlier. Management credits the CDMO sale, a gain on a Wilmington, Massachusetts site sale, lower accelerated amortization and a non-income tax benefit. The $201 million benefit came from reversing an unrecognized tax benefit reserve, money set aside for a tax position that might be challenged. For the nine months, net income also absorbed a $181.7 million loss on the CDMO and Cell Solutions sale.
  • Segments: In Discovery and Safety Assessment, higher regulated safety assessment revenue of $33.5 million nearly offset a $36.4 million drop from the European Discovery sale. In Manufacturing, Microbial Solutions revenue rose $7.2 million on endotoxin testing reagent demand. In Research Models and Services, small research model sales in China rose $4.9 million, while North America fell $3.8 million.
  • Cash and capital return: Operating cash flow for the nine months was $474.9 million, down from $590.1 million, on higher bonus payments and professional fees. The company repurchased 1.7 million shares for $300.0 million in that period, leaving $700.0 million of its $1.0 billion authorization. It also paid $100.0 million of deferred consideration for the Cambodian non-human primate supplier acquired in January 2026.

What management is watching

  • Demand: Management describes an improved spending environment, citing increased biotech funding and large drugmakers refocusing on early-stage research. Backlog in Discovery and Safety Assessment, work contracted but not yet performed, was $2.0 billion as of September 26, 2026, up from $1.9 billion as of December 27, 2025.
  • Cost savings: The "Create the Future" program, announced this quarter, expands existing efficiency efforts to include AI-enabled automation. The company expects approximately $300 million of cumulative annualized cost savings by the end of 2026, and incremental savings in excess of $300 million between 2027 and 2030. Restructuring charges were $19.2 million for the quarter and $73.8 million for the nine months.
  • Currency exposure: The filing says a 10% stronger U.S. dollar would have reduced nine-month revenue by $135.8 million and operating income by $33.2 million.
  • Measures to watch: The filing points to operating income as a percentage of revenue by segment and to the Discovery and Safety Assessment backlog. It gives no revenue or earnings outlook for the rest of the year.

Follow CRL in Kortex

The Kortex app shows CRL's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.